Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04714762 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

eHealth in Treatment of Gestational Diabetes (eMOMGDM)

Study acronym: eMOMGDM
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Dec 31, 2026 to Dec 31, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 7 of 18 entries
    • Study description expanded, about 27 words
    • Publications: details revised at 2 of 2 entries
  2. Study completion date: Dec 2024 to Dec 31, 2026v10
  3. Secondary endpoints: 17 to 18v9
  4. Primary completion date: Dec 13, 2022 to Dec 12, 2022v8
  5. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 31, 2022 to Dec 13, 2022
    • Study completion date: Dec 2023 to Dec 2024
    • Site details revised
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Secondary endpoints: 16 to 17
    • Eligibility criteria expanded, about 2 words
    v6
  2. Study description shortened, about 62 wordsv5
  3. Primary completion date: Jul 2022 to Dec 31, 2022
    • Secondary endpoints: 13 to 16
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2021 to Mar 10, 2021
    v3
  5. Start date: Feb 2021 to Mar 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aim of the eMOM GDM-project is to develop and evaluate a novel system to clinical decision making and patient behavior change in treatment of GDM, combining diet, physical activity, sleep, heart rate (e.g. stress), and glucose monitoring within a single system (the eMOM GDM application), and linking the developed application tool for the normal health care system in a new way. In this second phase of the project, the effect of eMOM GDM application on maternal and neonatal outcomes will be evaluated in a randomized controlled study design. The follow-up study continues until 3 months postpartum.
Trial Details
NCT Number NCT04714762
Lead Sponsor Helsinki University Central Hospital
Collaborators: University of Helsinki, Aalto University, UKK Institute, Tampere University, Finnish Institute for Health and Welfare, Fujitsu, Elisa Oyj, Business Finland
Conditions
(from sponsor)		 Gestational Diabetes, Mobile Application
Related terms Diabetes, Gestational, Motor Activity
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov